To assess time to progression to castrate-resistant prostate cancer (CRPC) and factors influencing longer-term outcomes in patients receiving androgen-deprivation therapy (ADT) in an extension to the Triptocare study (NCT01020448). This is pertinent as the Triptocare study did not show that urinary prostate cancer antigen-3 (PCA3) score was a reliable marker of cancer stage in advanced prostate cancer and was not useful for assessing response 6 months after initiation of ADT with triptorelin 22.5 mg.
(102 received continuous and 78 received intermittent ADT). CRPC rates at 3 years were 24/102 (23.5%) and 6/78 (7.7%) patients in the continuous and intermittent ADT groups, respectively. The median time to CRPC was not reached for either group. PCA3 score status at baseline was the only variable associated with a higher risk of progression to CRPC in both the intermittent and continuous ADT groups; compared with a baseline PCA3 score of ≥35, a PCA3 score below the level of quantification had a hazard ratio (HR) of 20.04 ([95% confidence interval (CI) 2.71-148.34] and a HR of 9.44 [95% CI 2.39-37.27], respectively). Baseline metastatic disease and testosterone level were additionally associated with progression to CRPC in the continuous ADT population (HR 5.20, 95% CI 1.68-16.06 and HR 0.995, 95% CI 0.991-0.999, respectively).
Introduction
Prostate cancer accounts for~23% of all male cancers, and 9.5% of all cancer deaths among men in Europe [1] . Androgen-deprivation therapy (ADT), with GnRH agonists or antagonists is an established and well-tolerated therapy for locally advanced or metastatic prostate cancer [2] . The efficacy and tolerability of the GnRH agonist triptorelin (Decapeptyl â , Ipsen, Paris, France) as a treatment for locally advanced or metastatic prostate cancer has been shown in many studies [3] [4] [5] [6] .
While most patients with prostate cancer initially respond to ADT, the disease can progress to castrate-resistant prostate cancer (CRPC). The ability to identify which patients are most likely to develop CRPC would be invaluable due to the poor prognosis of patients with CRPC. Therefore, there is a need for a reliable, simple and cost-effective surrogate marker that may be used to predict progression to and/or response of CRPC to treatment.
Assays are available to measure prostate cancer antigen-3 (PCA3) mRNA and PSA mRNA, and the PCA3 score derived from these measures [7] . The potential of PCA3 score as a predictor of progression to CRPC is unknown. Also, the fusion of type 2 transmembrane serine protease with v-erythroblastosis virus E26 oncogene homolog (TMPRSS2-ERG or T2-ERG) is a common gene fusion in prostate cancer occurring in 50% of all prostate cancers and is associated with aggressive recurring prostate cancer [8, 9] .
The Triptocare study showed that the urinary PCA3 score and T2-ERG score were not reliable markers of cancer stage in advanced prostate cancer and were not useful for assessing response 6 months after initiation of ADT with triptorelin 22.5 mg [5] . However, there are no long-term data on the usefulness of PCA3 or T2-ERG scores as markers for the prediction of the progression of prostate cancer to metastatic CRPC.
The present study investigated the rate of progression to CRPC, factors influencing the early onset of CRPC, the potential value of pretreatment PCA3 and T2-ERG scores, and serum PSA and testosterone levels to predict progression to CRPC over a 3-year period after the initiation of ADT in the Triptocare study.
Patients and Methods
The Triptocare LT study (ClinicalTrials.gov registry number NCT01383863) was an international, multicentre, noninterventional, observational, longitudinal and prospective study carried out at 34 centres in Europe that had previously participated in the Triptocare study [5] (ClinicalTrials.gov registry number NCT01020448).
The study was conducted in accordance with recommendations from the International Society for Pharmacoepidemiology (ISPE) and Good Pharmacoepidemiological Practice (GPP) Guidelines. The protocol was approved by all relevant Ethics Committees, Institutional Review Boards and Health Authorities.
Patients
Patients were eligible for inclusion in the Triptocare LT study if they had participated and received study treatment in the original Triptocare study [5] , were aware of the nature of the observational study, and had given written informed consent to participate. Patients who consented were enrolled into Triptocare LT after a 3-9 month interim period after the completion of the Triptocare study. For each patient a 3-year follow-up period from the date of the initiation of ADT in the Triptocare study was assessed.
Treatment
All treatment and assessment of patients was at the discretion of the investigator and while patients in the Triptocare study were treated with the triptorelin 6-month formulation, physicians could prescribe any GnRH analogue (agonist or antagonist) for patients in the Triptocare LT study. Patients included in this non-interventional study received standard of care for prostate cancer, according to local clinical practice and current treatment recommendations. The decision to prescribe any product or treatment at any time was to be taken independently from the decision to enrol the patient into the study. As there was no specific study treatment, any treatments received by patients were not supplied by the Sponsor. ADT could be administered either continuously (continuous ADT population) or intermittently (intermittent ADT population) during the study.
Outcomes
The co-primary endpoints were rate of CRPC at 3 years after the initiation of ADT and the median time to CRPC. Secondary endpoints were rate of disease progression (defined as the appearance of two or more new bone metastases on bone scan; progression of soft tissue lesions in nodal or visceral sites on physical examination or X-ray; or new pain experienced by the patient likely to be related to the prostate cancer; or two or more consecutive measurements of increasing PSA levels) at 3 years after the initiation of ADT; and serum PSA and serum testosterone profile for 3 years after the initiation of ADT. Exploratory endpoints were association of age, pathological grade (Gleason score), serum PSA level, serum testosterone level, metastatic disease and T2-ERG score status at the initiation of the Triptocare study, and PCA3 score status at the initiation and at last value available (LVA) of the Triptocare study (i.e., when patients had received ADT for 6 months), with progression to CRPC.
Assessments
CRPC was defined as a serum testosterone level of <50 ng/ dL plus the presence or appearance of one or more of the following symptoms of clinical progression: two or more consecutive measurements of increasing PSA over the nadir, with a PSA level of >2 ng/mL; two or more new bone metastases on bone scan; the development of nodal or visceral lesions; or bone pain, which in the opinion of the investigator was related to progression of the prostate cancer.
Urinary PCA3 and T2-ERG scores were measured at baseline for all patients enrolled in the Triptocare study, but these assessments were not performed in the Triptocare LT study, as the purpose of this study was to assess the impact of baseline variables only on CRPC development [5] . PCA3 and PSA mRNAs were quantified in each specimen using the PROGENSA PCA3 assay. PCA3 scores were calculated as 1 000 9 (PCA3 mRNA copies/PSA mRNA copies). A PCA3 score threshold of ≥35 was chosen in the original Triptocare study to provide a balance between specificity and sensitivity, and for the clinical utility shown in other studies, and the PCA3 score was considered below the limit of quantification (BLQ) when the PCA3 mRNA was below the limit or equal to the level of quantification (≤BLQ) [10, 11] . Non-assessable PCA3 scores were defined as samples with PSA mRNA <7 500 copies/mL. Similarly a T2-ERG score threshold of ≥35 was used to define a positive score [5] .
In the Triptocare LT study, PSA and testosterone levels were measured at local laboratories. Other baseline assessments included: patient characteristics (e.g., age, body mass index, body weight, and vital signs); medical history and previous therapy; and prostate cancer status (by Gleason score and TNM staging; classification following standard local practice).
As this was a non-interventional study, adverse events (AEs) were reported in line with regulations relating to spontaneous cases.
Statistical Analyses
Descriptive statistics including 95% CIs were used to describe the primary and secondary efficacy variables. The AgrestiCoull method was used to produce binomial CIs, and 95% CIs were provided for time-to-event analyses estimates of quartile and median survival time. Kaplan-Meier plots were used to describe time to CRPC. Identification of baseline characteristics from patients enrolled in the Triptocare study, and from the LVA of the PCA3 score, were associated with the occurrence of CRPC and were assessed using the Cox model. All variables with an associated P < 0.2 in the univariate analyses were selected. Then each parameter was tested with others at the 0.001 level to check that there was no strong link between them. All variables in the univariate analyses that were not linked were considered for multivariate analyses using a stepwise Cox regression model.
Results
Of the 325 patients included in the Triptocare safety population, 180 were enrolled into the Triptocare LT study (Fig. 1) .
Among those enrolled in the Triptocare LT study, 102 patients received ADT continuously and 78 had intermittent ADT during the observational phase. ADT consisted of GnRH agonist therapy in all patients, but in three patients receiving continuous ADT a GnRH antagonist was used as an alternative at some visits. Reported concomitant treatments included anti-androgens (29 and eight patients in the continuous and intermittent groups, respectively) and radiation therapy (seven patients in the continuous group).
Baseline characteristics of the 180 patients included in the Triptocare LT study were largely similar to the data for the Triptocare safety population, although there were slightly fewer patients with Gleason score ≥8, metastasis (M1) and stage T4 in the Triptocare LT study (Table 1) . Among those in the continuous ADT group there were more patients with advanced disease (Gleason score ≥8, M1 and T4) compared with the intermittent ADT group. The median baseline testosterone levels were lower but median PSA levels higher in the continuous ADT vs intermittent ADT group (Table 1) .
Disease Progression
At 3 years after starting ADT, CRPC had occurred in 30/180 (16.7%) patients, which meant that the median time to CRPC was not reached in the 3 years' follow-up. At 3 years after starting ADT, disease progression occurred in 41/180 (22.8%) patients. Disease progression was mostly defined as PSA progression (37 observations for 33 patients); in 10 observations for nine patients the presence of two or more new bone metastases was mentioned (either as the sole reason for progression or in combination with PSA progression or bone pain). There were 22 deaths during the Triptocare LT study (prostate cancer progression, six; other [not prostate cancer] cancer, two; heart failure/ cardiac arrest, two; gastrointestinal bleeding, one; sepsis, one; and unknown, 10).
CRPC occurred in 24/102 (23.5%) patients receiving continuous ADT and 6/78 (7.7%) patients receiving intermittent ADT. The median time to CRPC was not reached for either the continuous ADT or intermittent ADT groups (Fig. 2) . However, the 25th percentile time to CRPC for the continuous ADT population was calculated as 2.95 years (1 077 days). Disease progression was seen in 30/102 (29.4%) patients in the continuous ADT group and 11/78 (14.1%) patients in the intermittent ADT group.
Univariate analyses showed that age, pathological grade and T2-ERG score were not associated with an increased risk of CRPC for any of the groups (Table 2 ).
Multivariate analyses showed that in the whole population, metastatic disease (M1) at baseline was significantly associated with a greater risk of progression to CRPC compared with non-metastatic disease (M0) at baseline (Table 2) . A lower testosterone level at baseline was also significantly associated with a higher risk of progression to CRPC (Table 2) . A PCA3 score BLQ at baseline compared with a baseline PCA3 score of ≥35 was significantly associated with a higher risk of progression to CRPC (Table 2 ).
In the group receiving intermittent ADT, a PCA3 score BLQ at baseline compared with a baseline PCA3 score of ≥35 was significantly associated with a higher risk of progression to CRPC (Table 2 ). In the continuous ADT population, the same risk factors for CRPC were seen as in the whole population (i.e., M1, lower testosterone levels and a PCA3 score BLQ; Table 2 ).
Efficacy Endpoints
The median serum PSA and testosterone levels decreased during the Triptocare study and median levels of both these measures remained consistently low during the Triptocare LT study (Figs 3 and 4 , showing data for the whole population).
A maximum of 20% of patients in the continuous ADT group had their testosterone levels measured and almost all were castrated and maintained castration levels of testosterone (<50 ng/dL) over the study period.
The median (range) PSA nadir was 0.70 (0.01-312.11) ng/mL, and the median time to PSA nadir was 185 days.
Safety Analysis
There were 18 AEs reported during the Triptocare LT study period. AEs considered to be related to ADT were gynaecomastia (three events), increased weight (three events), hot flushes (two events), asthenia (one event), and erectile dysfunction (one event). There was one event of peripheral oedema that was not considered related to ADT. Details were not available for one event of formication. Due to the spontaneous nature of the reporting of AEs there are no severity data available. However, the reported AEs were as expected from previous studies with GnRH agonists. 
Discussion
Most men with locally advanced or metastatic prostate cancer who were enrolled in the Triptocare LT study completed the 3-year follow-up period and 16.7% developed CRPC during this time (23.5% in the continuous ADT population and 7.7% in the intermittent population). The higher rate of CRPC in the continuous ADT population than in the intermittent ADT population could be a result of random variation (as the study was not powered to measure differences between the two populations). Alternatively, one could speculate that this difference reflects a greater likelihood for continuous ADT use in patients who have been assessed as having a high risk of progression (thus selecting a population that is more likely to progress irrespective of treatment). However, the Triptocare LT study was not designed to compare the relative efficacy of intermittent and continuous ADT, and therefore, no firm conclusion can be drawn about this difference.
Concentrations of serum PSA and testosterone remained low throughout the study. The frequency and type of AEs in the present study are consistent with those expected for GnRH analogues [4, 12, 13] . At 3 years after initiation of ADT, 17.5% (57/325) of patients from the original Triptocare study had died. This figure is consistent with mortality rates reported for populations across Europe [14] .
In the present study, the definition of CRPC was based on European Association of Urology guidelines [2] , which considered that CRPC had occurred when a patient with a serum testosterone level of <50 ng/dL developed one or more symptoms of clinical progression. However, in the 'real-world clinical practice' setting of the Triptocare LT study, the diagnosis of CRPC was not always associated with a current measurement of serum testosterone concentration. Due to the variability of local standard of care in clinical practice, the evaluation of endpoints can be challenging for 'real-world' studies such as this one. Therefore, for some patients, the diagnosis of CRPC appears to be based upon the clinician's personal experience when assessing individual patient's symptoms, but could be an over-estimate if testosterone levels were actually elevated in some patients.
The Triptocare study showed that in a small subgroup of patients with high PCA3 scores at baseline, PCA3 scores remained high after 6 months of treatment [5] . Therefore, it *If the centralised Gleason score was not available the local Gleason score was used; BLQ, below the limit of quantification; BMI, body mass index.
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© 2016 The Authors BJU International © 2016 BJU International was interesting to follow these patients for a longer period to determine if high PCA3 score at baseline was a risk factor for progression to CRPC. Follow-up of patients for 3 years in our present study indicated that a PCA3 score of ≥35 when initiating ADT may predict a lower risk of developing CRPC in the following 3 years.
In the Triptocare study, patients with metastatic prostate cancer had significantly lower PCA3 scores than men with no metastases [5] . Also, it has been reported that PCA3 mRNA expression is reduced in higher grade tumours and lower levels of PCA3 mRNA are expressed in patients with CRPC resulting in reduced PCA3 score [15] . The results from the Triptocare LT study, therefore, may suggest that there is a population with low PCA3 scores and metastatic prostate cancer that are at greater risk of progression to CRPC. The upregulation of PCA3 expression appears to be restricted to cells that express androgen receptors [16] . However, it has recently been hypothesised that the continued production of androgens within circulating tumour cells and/or within metastasised tumours contributes to the emergence of metastatic CRPC [17] [18] [19] [20] . Clearly further studies are needed to resolve the relationships between PCA3 score and CRPC development, and to elucidate possible mechanisms for any such relationships.
The data from the present study indicate that T2-ERG is not a useful prognostic biomarker for patients with advanced prostate cancer. These findings are in agreement with the initial results obtained during the Triptocare study, which suggested that T2-ERG was not a reliable marker of cancer stage given that there was no obvious relationship between baseline T2-ERG score and clinical stage or pathological grade of cancer [5] . The findings also agree with a recent report that showed that T2-ERG is not a marker for progression to CRPC in patients with advanced prostate cancer [21] .
Although not all patients had testosterone levels measured at all visits, when measurements were taken, most patients remaining on ADT remained castrated (e.g., 92% of patients [23/25] with a testosterone measurement at month 33 had castration levels of testosterone, which is similar to the percentage reported in other studies over a shorter time interval) [4, 5] .
There were limitations to the statistical analyses including the median time to CRPC not being reached, low number of events, such as, low number of patients in the continuous ADT group with testosterone levels, the wide CIs for the HRs, and the lack of power calculations.
In conclusion, in men with locally advanced or metastatic prostate cancer receiving continuous or intermittent ADT, a PCA3 score ≥35 at the time of initiating ADT may predict a lower risk of developing CRPC in the subsequent 3 years. A low testosterone level or the presence of metastasis at the time of initiating ADT may predict a higher risk of developing CRPC. Further studies on the potential predictive role of PCA3 scores in advanced prostate cancer are needed. The median serum testosterone levels (ng/dL) at 9-33 months after initiation of ADT. The baseline value for the patients included in the Triptocare LT study (180 patients) measured at inclusion into the Triptocare study. Vertical arrow denotes the start of the Triptocare LT study.
